Featuring an interview with Dr Michael Pishvaian, including the following topics:


• Importance of next-generation sequencing as part of the diagnostic workup for metastatic pancreatic cancer (0:00)

• Optimal treatment selection for patients with germline BRCA mutation-positive pancreatic cancer (3:32)

• NAPOLI-3 Phase III trial of liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for treatment-naïve metastatic pancreatic ductal carcinoma (5:48)

• Perspectives on the comparative efficacy and tolerability of 2-drug and 3-drug treatment regimens in the metastatic setting; perioperative versus adjuvant therapy in locally advanced disease (9:22)

• Novel treatment approaches for pancreatic cancer — zolbetuximab, tumor treating fields and intra-arterial gemcitabine (14:35)

• Role of radiation therapy in the management of pancreatic cancer; early-phase data with novel antibody-drug conjugates (22:14)

• Selection of second-line therapy for metastatic pancreatic cancer (26:15)

• PARP inhibition for the treatment of pancreatic cancer (32:27)

• Investigational approaches for the treatment of KRAS mutation-positive pancreatic cancer (48:50)

• Vaccine-based treatment approaches under development for pancreatic cancer; palliative care strategies (52:04)


CME information and select publications ([ Ссылка ])

свернуть